Tysabri and PML: What the Evidence Shows About Risk and Recovery

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Literacy to Occupational Hazard Awareness

If you or a loved one takes Tysabri for multiple sclerosis or Crohn's disease, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). This page summarizes what current medical evidence can and cannot tell us about PML risk, early symptoms, and the likelihood of recovery. Building on decades of research into JC virus and immunosuppression, we provide a clear overview of the key facts every patient should know.

Understanding Tysabri and Its Link to PML

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The question of whether PML from Tysabri is permanent is critical for patients and clinicians assessing the risk-benefit profile of this medication. The prognosis for Tysabri-associated PML is poor. According to the FDA-approved prescribing information, PML "usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This statement is based on clinical trial data and post-marketing surveillance. In clinical trials, PML occurred in three patients who received Tysabri: two cases were observed among 1869 multiple sclerosis patients treated for a median of 120 weeks, and one case occurred after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These cases highlight that PML can develop even with relatively short exposure, though longer treatment duration, especially beyond two years, is a known risk factor (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Is PML from Tysabri Permanent?

The permanence of PML is a central concern. The infection causes progressive damage to the white matter of the brain, leading to neurological deficits that are often irreversible. While some patients may survive PML, the label explicitly states that it "usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This means that even in survivors, significant and lasting neurological impairment is common. The damage to brain tissue from JC virus replication is typically not reversible, making PML a permanent condition in most cases. The timeline between Tysabri exposure and the development of PML varies. The label identifies three key risk factors: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML can occur during treatment, but it has also been reported after discontinuation of Tysabri in patients who did not have findings suggestive of PML at the time of stopping therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This delayed onset underscores the need for continued monitoring. The label recommends that patients be monitored for any new signs or symptoms that may be suggestive of PML for at least six months following discontinuation of Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Risk Communication and Prognostic Factors

The adequacy of warnings regarding Tysabri and PML is reflected in the boxed warning, which is the strongest safety alert issued by the FDA. The warning states that Tysabri increases the risk of PML and that the infection "usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label also mandates that Tysabri be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Additionally, Tysabri is only available through a restricted distribution program called the TOUCH Prescribing Program, which is designed to ensure that patients are informed of the risks and that monitoring is conducted (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These measures indicate that the risks are clearly communicated, but the prognosis remains severe. For patients who develop PML, the prognosis is influenced by several factors, including the extent of brain involvement at diagnosis, the patient's immune status, and the speed of intervention. However, the label does not provide specific survival rates or recovery outcomes beyond stating that PML "usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This underscores the permanent and devastating nature of the condition.

Conclusion: Permanent Consequences and Ongoing Monitoring

In summary, PML from Tysabri is typically permanent, resulting in death or severe disability. The risk is clearly communicated through boxed warnings and a restricted distribution program. The timeline for PML development can extend beyond treatment discontinuation, necessitating prolonged monitoring. Patients and clinicians must weigh these risks against the benefits of Tysabri therapy. References: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Is Progressive Multifocal Leukoencephalopathy from Tysabri permanent?

Yes, PML from Tysabri is typically permanent. The infection causes progressive damage to the brain's white matter, leading to neurological deficits that are often irreversible. According to the FDA-approved label, PML "usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Even in survivors, significant and lasting impairment is common.

What are the risk factors for developing PML while on Tysabri?

The label identifies three key risk factors: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML can occur during treatment or even after discontinuation, so monitoring is essential.

How long after stopping Tysabri should I be monitored for PML?

The label recommends monitoring for any new signs or symptoms suggestive of PML for at least six months following discontinuation of Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Delayed onset has been reported.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed - Tysabri Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.